A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 171 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Pumpkin Season! October 27, 2020 Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 Load more HOT NEWS Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ Teacher Reads To Students One Day After Having Brain Surgery Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib...
